HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents

Oncogene

Volumn 30, Issue 27, 2011, Pages 3024-3035

  Palmieri, D ^a,c   Valentino, T ^a   D'Angelo, D ^a   De Martino, I ^a   Postiglione, I ^a   Pacelli, R ^b   Croce, C M ^c   Fedele, M ^a   Fusco, A ^a,d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c OHIO STATE UNIVERSITY   (United States)

^d CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

ATM; DNA repair; HMGA

Indexed keywords

ACTIN; ATM PROTEIN; HIGH MOBILITY GROUP A PROTEIN; HIGH MOBILITY GROUP A1 PROTEIN; HIGH MOBILITY GROUP A2 PROTEIN; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; VINCULIN;

ANIMAL CELL; ARTICLE; ATM GENE; CANCER RELAPSE; CANCER RESISTANCE; CELL STRESS; CELL TRANSFORMATION; CONTROLLED STUDY; DNA DAMAGE; EMBRYO; ENZYME INDUCTION; GENE; GENE EXPRESSION; GENOTOXICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FAMILY; TRANSCRIPTION INITIATION;

ANIMALS; CELL CYCLE PROTEINS; CELL LINE; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA PROTEINS; HUMANS; MUTAGENS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA;

EID: 79960065049     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.21     Document Type: Article

References (41)

1. Bakkenist CJ, Kastan MB. (2003). DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421: 499-506. (Pubitemid 36168436)
2. Berkovich E, Ginsberg D. (2003). ATM is a target for positive regulation by E2F-1. Oncogene 22: 161-167. (Pubitemid 36174173)
3. Berlingieri MT, Pierantoni GM, Giancotti V, Santoro M, Fusco A. (2002). Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene 21: 2971-2980. (Pubitemid 34522896)
4. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K et al. (1998). Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281: 1677-1679. (Pubitemid 28435584)
5. Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F et al. (1996). High level expression of the HMGI (Y) gene during embryonic development. Oncogene 13: 2439-2446. (Pubitemid 27026027)
6. Crescenzi E, Palumbo G, de Boer J, Brady HJ. (2008). Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: implications for chemotherapy. Clin Cancer Res 14: 1877-1887. (Pubitemid 351469475)
7. d'Adda di Fagagna F (2008) Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer, 8, 512-522. (Pubitemid 351881854)
8. Fedele M, Battista S, Manfioletti G, Croce CM, Giancotti V, Fusco A. (2001a). Role of the high mobility group A proteins in human lipomas. Carcinogenesis 22: 1583-1591. (Pubitemid 32952135)
9. Fedele M, Fusco A. (2010). HMGA and cancer. Biochim Biophys Acta 1799: 48-54.
10. Fedele M, Pierantoni GM, Berlingieri MT, Battista S, Baldassarre G, Munshi N et al. (2001b). Overexpression of proteins HMGA1 induces cell cycle deregulation and apoptosis in normal rat thyroid cells. Cancer Res 61: 4583-4590. (Pubitemid 32685793)
11. Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S et al. (2006). HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 9: 459-471. (Pubitemid 43832192)
12. Fusco A, Fedele M. (2007). Roles of HMGA proteins in cancer. Nat Rev Cancer 7: 899-910. (Pubitemid 350165857)
13. Gueven N, Keating K, Fukao T, Loeffler H, Kondo N, Rodemann HP et al. (2003). Site-directed mutagenesis of the ATM promoter: consequences for response to proliferation and ionizing radiation. Genes Chromosomes Cancer 38: 157-167. (Pubitemid 37093433)
14. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI et al. (2004). Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64: 9152-9159. (Pubitemid 39665530)
15. Jackson SP. (2009). The DNA-damage response: new molecular insights and new approaches to cancer therapy. Biochem Soc Trans 37: 483-494.
16. Johnson KR, Lehn DA, Reeves R. (1989). Alternative processing of mRNAs encoding mammalian chromosomal high-mobility-group proteins HMG-I and HMG-Y. Mol Cell Biol 9: 2114-2123. (Pubitemid 19117812)
17. Kuhne M, Riballo E, Rief N, Rothkamm K, Jeggo PA, Lobrich MA. (2004). Double-strand break repair defect in ATM-deficient cells contributes to radiosensitivity. Cancer Res 64: 500-508. (Pubitemid 38120888)
18. Lavin MF. (2008). Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 9: 759-769.
19. Lavin MF, Kozlov S. (2007). ATM activation. DNA damage response. Cell Cycle 6: 931-942. (Pubitemid 46658748)
20. Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
21. Martinez Hoyos J, Fedele M, Battista S, Pentimalli F, Kruhoffer M, Arra C et al. (2004). Identification of the genes up- and down-regulated by the high mobility group A1 (HMGA1) proteins: tissue specificity of the HMGA1-dependent gene regulation. Cancer Res 64: 5728-5735. (Pubitemid 39095571)
22. Meyn MS, Strasfeld L, Allen C. (1994). Testing the role of p53 in the expression of genetic instability and apoptosis in ataxia-telangiecta-sia. Int J Radiat Biol 66: S141-S149.
23. Nagpal S, Ghosn C, DiSepio D, Molina Y, Sutter M, Klein ES et al. (1999). Retinoid-dependent recruitment of a histone H1 displacement activity by retinoic acid receptor. J Biol Chem 274: 22563-22568.
24. Narita M, Narita M, Krizhanovsky V, Nunez S, Chicas A, Hearn SA et al. (2006). A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 126: 503-514. (Pubitemid 44163608)
25. O'Neill T, Dwyer AJ, Ziv Y, Chan DW, Lees-Miller SP, Abraham RH et al. (2000). Utilization of oriented peptide libraries to identify substrate motifs selected by ATM. J Biol Chem 275: 22719-22727. (Pubitemid 30646153)
26. Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, Campisi J. (2003). Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol 5: 741-747. (Pubitemid 36986782)
27. Pentimalli F, Palmieri D, Pacelli R, Garbi C, Cesari R, Martin E et al. (2008). HMGA1 protein is a novel target of the ATM kinase. Eur J Cancer 44: 2668-2679.
28. Pierantoni GM, Fedele M, Pentimalli F, Benvenuto G, Pero R, Viglietto G et al. (2001). High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth. Oncogene 20: 6132-6141. (Pubitemid 32964425)
29. Pierantoni GM, Rinaldo C, Esposito F, Mottolese M, Soddu S, Fusco A. (2006). High Mobility Group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. Cell Death Differ 5: 2045-2048.
30. Pierantoni GM, Rinaldo C, Mottolese M, Di Benedetto A, Esposito F, Soddu S et al. (2007). High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J Clin Invest 117: 693-702. (Pubitemid 46348527)
31. Reeves R, Adair JE. (2005). Role of high mobility group (HMG) chromatin proteins in DNA repair. DNA Repair (Amst) 8: 926-938. (Pubitemid 40961597)
32. Reeves R, Nissen MS. (1990). The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem 265: 8573-8582.
33. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM et al. (1999). Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 59: 4375-4382. (Pubitemid 29418757)
34. Sarkaria JN, Eshleman JS. (2001). ATM as a target for novel radiosensitizers. Semin Radiat Oncol 11: 316-327. (Pubitemid 32959666)
35. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. (1998). Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 58: 4375-4382. (Pubitemid 28450040)
36. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L et al. (1995). A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268: 1749-1753.
37. Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D et al. (2009). Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 457: 51-56.
38. Wood LJ, Maher JF, Bunton TE, Resar LM. (2000). The oncogenic properties of the HMG-I gene family. Cancer Res 60: 4256-4261. (Pubitemid 30636614)
39. Xu Y, Ashley T, Brainerd EE, Bronson RT, Meyn MS, Baltimore D. (1996). Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev 10: 2411-2422. (Pubitemid 26341877)
40. Xu Y, Yang EM, Brugarolas J, Jacks T, Baltimore D. (1998). Involvement of p53 and p21 in cellular defects and tumorigenesis in Atm-/- mice. Mol Cell Biol 18: 4385-4390. (Pubitemid 28287961)
41. Zhou X, Benson KF, Ashar HR, Chada K. (1995). Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C Nature 376: 771-774.